XCancer

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Description:

The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Phase:

N/A

Contacts:

Ning Xu, Doctor (CONTACT)

drxun@fjmu.edu.cn

13235907575

Xiao-Dong Li, Master (CONTACT)

lixiaodong@fjmu.edu.cn

15980273075

Xue-Yi Xue, Master (STUDY_CHAIR)

Government Study Link:

NCT06421142 - Click here to see study on

ClinicalTrials.gov

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules
Inclusion
  • Completion of FAPI PET/MRI, FDG PET/MRI and MRI;
  • Patients with suspected muscle-invasive bladder cancer;
  • Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study
  • * Inclusion criteria for MIBC diagnostic studies
  • Complete clinical laboratory and pathological data.
Exclusion
  • Not receiving surgical treatment;
  • Combined with other malignant tumors;
  • * Exclusion criteria for MIBC diagnostic study
  • Previous allergy to contrast components or similar components;
  • Receiving neoadjuvant therapy before surgery;